I. Expression across cell types
Name | Number of supported studies  | Average coverage | |
|---|---|---|---|
| type II pneumocyte | 6 studies | 48% ± 12% | |
| acinar cell | 3 studies | 90% ± 11% |
Name | Number of supported studies | Average coverage | |
|---|---|---|---|
| type II pneumocyte | 6 studies | 48% ± 12% | |
| acinar cell | 3 studies | 90% ± 11% |
Name | Number of supported studies | Average coverage | |
|---|---|---|---|
| pancreas | 3 studies | 31% ± 15% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
|---|---|---|---|---|---|---|
| pancreas | 100% | 433566.76 | 328 / 328 | 79% | 1956.54 | 140 / 178 |
| lung | 96% | 508.59 | 556 / 578 | 57% | 11.43 | 663 / 1155 |
| liver | 81% | 63.16 | 183 / 226 | 71% | 7.40 | 289 / 406 |
| adrenal gland | 100% | 123.45 | 258 / 258 | 45% | 44.22 | 103 / 230 |
| ovary | 97% | 156.38 | 175 / 180 | 33% | 1.89 | 140 / 430 |
| kidney | 76% | 41.31 | 68 / 89 | 43% | 1.27 | 387 / 901 |
| stomach | 86% | 126.68 | 308 / 359 | 17% | 55.65 | 48 / 286 |
| prostate | 57% | 67.76 | 139 / 245 | 25% | 0.47 | 128 / 502 |
| uterus | 62% | 35.98 | 106 / 170 | 13% | 0.33 | 60 / 459 |
| spleen | 75% | 51.60 | 180 / 241 | 0% | 0 | 0 / 0 |
| bladder | 57% | 21.05 | 12 / 21 | 11% | 1.65 | 57 / 504 |
| intestine | 52% | 40.75 | 500 / 966 | 14% | 49.38 | 76 / 527 |
| esophagus | 50% | 50.64 | 726 / 1445 | 11% | 0.66 | 20 / 183 |
| breast | 45% | 105.78 | 206 / 459 | 16% | 0.30 | 181 / 1118 |
| skin | 38% | 32.43 | 679 / 1809 | 14% | 0.30 | 68 / 472 |
| thymus | 42% | 29.58 | 274 / 653 | 5% | 0.14 | 30 / 605 |
| brain | 31% | 19.03 | 816 / 2642 | 16% | 0.25 | 113 / 705 |
| eye | 0% | 0 | 0 / 0 | 43% | 0.98 | 34 / 80 |
| blood vessel | 41% | 84.68 | 550 / 1335 | 0% | 0 | 0 / 0 |
| adipose | 40% | 144.21 | 482 / 1204 | 0% | 0 | 0 / 0 |
| peripheral blood | 36% | 20.47 | 332 / 929 | 0% | 0 | 0 / 0 |
| heart | 36% | 34.41 | 307 / 861 | 0% | 0 | 0 / 0 |
| muscle | 30% | 18.43 | 243 / 803 | 0% | 0 | 0 / 0 |
| lymph node | 0% | 0 | 0 / 0 | 10% | 0.17 | 3 / 29 |
| tonsil | 0% | 0 | 0 / 0 | 2% | 0.03 | 1 / 45 |
| abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
| GO_0048146 | Biological process | positive regulation of fibroblast proliferation |
| GO_0032869 | Biological process | cellular response to insulin stimulus |
| GO_0010524 | Biological process | positive regulation of calcium ion transport into cytosol |
| GO_0019731 | Biological process | antibacterial humoral response |
| GO_0007165 | Biological process | signal transduction |
| GO_0019370 | Biological process | leukotriene biosynthetic process |
| GO_0030593 | Biological process | neutrophil chemotaxis |
| GO_0016042 | Biological process | lipid catabolic process |
| GO_0043406 | Biological process | positive regulation of MAP kinase activity |
| GO_0051092 | Biological process | positive regulation of NF-kappaB transcription factor activity |
| GO_0050714 | Biological process | positive regulation of protein secretion |
| GO_0006633 | Biological process | fatty acid biosynthetic process |
| GO_0002446 | Biological process | neutrophil mediated immunity |
| GO_0035556 | Biological process | intracellular signal transduction |
| GO_1904635 | Biological process | positive regulation of podocyte apoptotic process |
| GO_0050830 | Biological process | defense response to Gram-positive bacterium |
| GO_0032431 | Biological process | activation of phospholipase A2 activity |
| GO_0007015 | Biological process | actin filament organization |
| GO_0032757 | Biological process | positive regulation of interleukin-8 production |
| GO_0046470 | Biological process | phosphatidylcholine metabolic process |
| GO_0006644 | Biological process | phospholipid metabolic process |
| GO_0008284 | Biological process | positive regulation of cell population proliferation |
| GO_0061844 | Biological process | antimicrobial humoral immune response mediated by antimicrobial peptide |
| GO_0050778 | Biological process | positive regulation of immune response |
| GO_0002227 | Biological process | innate immune response in mucosa |
| GO_0046471 | Biological process | phosphatidylglycerol metabolic process |
| GO_0046324 | Biological process | regulation of glucose import |
| GO_0045944 | Biological process | positive regulation of transcription by RNA polymerase II |
| GO_0050482 | Biological process | arachidonic acid secretion |
| GO_0005615 | Cellular component | extracellular space |
| GO_0005576 | Cellular component | extracellular region |
| GO_0009986 | Cellular component | cell surface |
| GO_0047498 | Molecular function | calcium-dependent phospholipase A2 activity |
| GO_0005543 | Molecular function | phospholipid binding |
| GO_0004623 | Molecular function | phospholipase A2 activity |
| GO_0005102 | Molecular function | signaling receptor binding |
| GO_0032052 | Molecular function | bile acid binding |
| GO_0005509 | Molecular function | calcium ion binding |
| Gene name | PLA2G1B |
| Protein name | Phospholipase A2 (EC 3.1.1.4) Phospholipase A2 (EC 3.1.1.4) (Group IB phospholipase A2) (Phosphatidylcholine 2-acylhydrolase 1B) |
| Synonyms | PPLA2 PLA2 PLA2A |
| Description | FUNCTION: Secretory calcium-dependent phospholipase A2 that primarily targets dietary phospholipids in the intestinal tract . Hydrolyzes the ester bond of the fatty acyl group attached at sn-2 position of phospholipids (phospholipase A2 activity) with preference for phosphatidylethanolamines and phosphatidylglycerols over phosphatidylcholines . May play a role in the biosynthesis of N-acyl ethanolamines that regulate energy metabolism and inflammation in the intestinal tract. Hydrolyzes N-acyl phosphatidylethanolamines to N-acyl lysophosphatidylethanolamines, which are further cleaved by a lysophospholipase D to release N-acyl ethanolamines (By similarity). May act in an autocrine and paracrine manner . Upon binding to the PLA2R1 receptor can regulate podocyte survival and glomerular homeostasis . Has anti-helminth activity in a process regulated by gut microbiota. Upon helminth infection of intestinal epithelia, directly affects phosphatidylethanolamine contents in the membrane of helminth larvae, likely controlling an array of phospholipid-mediated cellular processes such as membrane fusion and cell division while providing for better immune recognition, ultimately reducing larvae integrity and infectivity (By similarity). . |
| Accessions | F8W062 Q9BS22 ENST00000549767.1 P04054 ENST00000308366.9 ENST00000423423.3 |
